Angle PLC Announces Notice of Results
ANGLE plc (OTCQX:ANPCY), a pioneering liquid biopsy company specializing in circulating tumour cell (CTC) diagnostic solutions, has scheduled the release of its interim results for H1 2025 on September 9, 2025.
The company will host a virtual analyst meeting at 11:00 am BST due to planned tube strikes. The event will include a live webcast accessible through ANGLE's Investor Centre page, with Q&A participation limited to analysts. A recording will be made available on the company's website after the meeting.
ANGLE plc (OTCQX:ANPCY), azienda all'avanguardia nelle biopsie liquide specializzata in soluzioni diagnostiche per cellule tumorali circolanti (CTC), ha programmato la pubblicazione dei risultati interim per il primo semestre 2025 il 9 settembre 2025.
Per effetto di scioperi programmati della metropolitana, la società terrà una riunione virtuale con gli analisti alle 11:00 BST. L'evento comprenderà una diretta web consultabile tramite la pagina Investor Centre di ANGLE; la sessione di domande e risposte sarà riservata agli analisti. La registrazione sarà disponibile sul sito aziendale dopo l'incontro.
ANGLE plc (OTCQX:ANPCY), una empresa pionera en biopsias líquidas especializada en soluciones diagnósticas para células tumorales circulantes (CTC), ha programado la publicación de sus resultados interinos del primer semestre de 2025 para el 9 de septiembre de 2025.
Debido a huelgas planificadas en el metro, la compañía celebrará una reunión virtual con analistas a las 11:00 BST. El evento incluirá una retransmisión en directo accesible desde la página Investor Centre de ANGLE; las preguntas y respuestas estarán limitadas a los analistas. La grabación se publicará en la web de la compañía tras la reunión.
ANGLE plc (OTCQX:ANPCY)는 순환종양세포(CTC) 진단 솔루션을 전문으로 하는 선도적인 액체생검 기업으로, 2025년 상반기 중간 실적을 2025년 9월 9일에 발표할 예정입니다.
예정된 지하철 파업으로 인해 회사는 영국식 표준시 기준 오전 11시( BST)에 애널리스트 대상 온라인 회의를 개최합니다. 행사는 ANGLE의 Investor Centre 페이지를 통해 실시간 웹캐스트로 제공되며, 질의응답은 애널리스트에 한해 참여할 수 있습니다. 회의 후 녹화본은 회사 웹사이트에 게시될 예정입니다.
ANGLE plc (OTCQX:ANPCY), société pionnière dans la biopsie liquide spécialisée dans les solutions diagnostiques pour les cellules tumorales circulantes (CTC), a prévu de publier ses résultats intermédiaires du premier semestre 2025 le 9 septembre 2025.
En raison de grèves de métro programmées, la société tiendra une réunion virtuelle avec les analystes à 11h00 BST. L'événement sera diffusé en direct via la page Investor Centre d'ANGLE ; la session de questions-réponses sera réservée aux analystes. L'enregistrement sera mis en ligne sur le site de la société après la réunion.
ANGLE plc (OTCQX:ANPCY), ein führendes Unternehmen im Bereich Liquid Biopsy mit Fokus auf diagnostische Lösungen für zirkulierende Tumorzellen (CTC), hat die Veröffentlichung der Zwischenabschlüsse für das erste Halbjahr 2025 für den 9. September 2025 angekündigt.
Wegen geplanter U-Bahn-Streiks wird die Gesellschaft ein virtuelles Analysten-Meeting um 11:00 Uhr BST abhalten. Die Veranstaltung wird per Live-Webcast über die Investor Centre-Seite von ANGLE zugänglich sein; die Q&A-Sitzung ist auf Analysten beschränkt. Eine Aufzeichnung wird nach dem Meeting auf der Firmenwebseite verfügbar sein.
- None.
- None.
ANGLE plc ("the Company") Notice of Interim Results and Webcast
GUILDFORD, SURREY / ACCESS Newswire / September 5, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, will be releasing its interim results for the six months ended 30 June 2025 on Tuesday 9 September 2025.
A meeting for analysts will be held at 11:00 am BST on Tuesday 9 September 2025. In light of the planned tube strikes this will be held virtually.
A live webcast of the analyst meeting can be accessed via ANGLE's Investor Centre page, https://angleplc.com/investor-relations/corporate-presentations/, with Q&A participation reserved for analysts only. Please register in advance and log on to the webcast approximately 5 minutes before 11:00 am on the day of the results. A recording of the webcast will be made available on ANGLE's website following the results meeting.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director | |
Berenberg (NOMAD and Corporate Broker) Toby Flaux, Ciaran Walsh, Milo Bonser | +44 (0) 20 3207 7800 |
FTI Consulting Simon Conway, Sam Purewal Matthew Ventimiglia (US) | +44 (0) 203 727 1000 +1 (212) 850 5624 |
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
When will ANGLE plc (ANPCY) release its H1 2025 interim results?
How can investors access ANGLE plc's H1 2025 results presentation?
What is ANGLE plc's main business focus?
Why is ANGLE plc's analyst meeting being held virtually?
